Dashboard
Manage Tickers

ME23andMe Holding Co.

Nasdaq 23andme.com


$ 0.38 $ 0.00 (-0.26 %)    

Friday, 02-Aug-2024 15:59:10 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 447.95 $ -10.91 (-2.37 %)
DIA $ 397.31 $ -6.10 (-1.51 %)
SPY $ 532.92 $ -10.11 (-1.86 %)
TLT $ 98.17 $ 2.97 (3.12 %)
GLD $ 225.36 $ -0.43 (-0.19 %)
$ 0.382
$ 0.38 x 115
$ 0.38 x 100
-- - --
$ 0.35 - $ 1.79
3,478,247
na
181.83M
$ 1.84
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-30-2024 03-31-2024 10-K
2 02-07-2024 12-31-2023 10-Q
3 11-08-2023 09-30-2023 10-Q
4 08-08-2023 06-30-2023 10-Q
5 05-25-2023 03-31-2023 10-K
6 02-08-2023 12-31-2022 10-Q
7 11-07-2022 09-30-2022 10-Q
8 08-09-2022 06-30-2022 10-Q
9 05-27-2022 03-31-2022 10-K
10 02-11-2022 12-31-2021 10-Q
11 11-10-2021 09-30-2021 10-Q
12 08-13-2021 06-30-2021 10-Q
13 06-03-2021 03-31-2021 10-Q
14 03-24-2021 12-31-2020 10-K
15 11-16-2020 09-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

23andme-special-committee-responds-to-ceos-take-private-proposal-says-in-the-absence-of-a-revised-offer-at-a-more-appropriate-price-per-share-that-meets-the-other-requirements-set-forth-above-we-will-pursue-other-alternatives-in-striving-to-maximize-value-for-all-shareholders
23andMe Special Committee Responds To CEO'...
08/02/2024 12:08:22

23andme-receives-preliminary-non-binding-proposal-from-ceo-anne-wojcicki-to-acquire-all-outstanding-shares-not-owned-by-her-or-affiliates-for-040-per-share
23andMe Receives Preliminary Non-Binding P...
08/01/2024 12:02:33

Special Committee Reviewing Proposal With Wells Fargo As Financial Advisor And Dechert LLP As Legal Advisor

23andme-in-collaboration-with-20-lung-cancer-advocacy-organizations-announced-a-new-study-to-help-advance-research-in-lung-cancer
23andMe In Collaboration With 20 Lung Canc...
07/25/2024 11:36:06

The focus of the Lung Cancer Genetics Study is to better understand the genetics of people with lung cancer in order to improve...

23andme-and-nightingale-health-announced-a-strategic-collaboration-to-pilot-nightingale-healths-blood-metabolomics-panel-with-a-cohort-of-23andme-members
23andMe And Nightingale Health Announced A...
06/28/2024 11:33:12

As part of the pilot, 23andMe will offer up to 5,000 23andMe+ Premium and Total Health members the opportunity to receive blood...

looking-into-23andme-holdings-recent-short-interest
Looking Into 23andMe Holding's Recent Shor...
06/12/2024 19:15:21

Core News & Articles
Canada Authority Says Canada And UK Privac...
06/10/2024 14:12:14

- Reuters

23andme-therapeutics-present-preliminary-phase-2-safety-and-efficacy-results-for-23me-00610-targeting-cd200r1-at-the-2024-asco-annual-meeting
23andMe Therapeutics Present Preliminary P...
06/03/2024 12:21:59

– 23ME-00610 monotherapy demonstrates preliminary evidence of clinical benefit, including one confirmed partial response – 23ME...

12-health-care-stocks-moving-in-thursdays-after-market-session
12 Health Care Stocks Moving In Thursday's...
05/23/2024 20:31:02

23andme-board-on-mar-28-formed-special-committee-to-review-strategic-alternatives-for-maximizing-shareholder-value-on-apr-18-announced-ceo-anne-wojcicki-considering-proposal-to-acquire-remaining-outstanding-shares-says-in-light-of-review-not-providing-guidance
23andMe Board On Mar. 28 Formed Special Co...
05/23/2024 20:11:25

23andme-holding-q4-2024-gaap-eps-043-sales-64028m-beat-55822m-estimate
23andMe Holding Q4 2024 GAAP EPS $(0.43), ...
05/23/2024 20:07:32

23andMe Holding (NASDAQ:ME) reported quarterly losses of $(0.43) per share. The company reported quarterly sales of $64.028 mi...

Core News & Articles
Petros Pharmaceuticals Launches U.S. Distr...
05/14/2024 13:23:12

Lemonaid Health will offer customers more affordable access to branded ED medication STENDRA that may be taken as early as ~15 ...

23andme-holding-granted-additional-180-days-or-until-nov-4-to-regain-compliance-with-minimum-bid-price-requirement-for-continued-listing
23andMe Holding Granted Additional 180 Day...
05/10/2024 20:30:31

-SEC Filing

23andme-to-present-preliminary-efficacy-and-biomarker-data-for-23me-00610-at-the-2024-asco-annual-meeting
23andMe To Present Preliminary Efficacy An...
04/24/2024 20:51:50

23andMe Holding Co. (NASDAQ:ME) ("23andMe"), a leading human genetics and biopharmaceutical company, today announced th...

nasdaq-down-05-lithium-americas-shares-slide
Nasdaq Down 0.5%; Lithium Americas Shares ...
04/18/2024 18:54:52

12-health-care-stocks-moving-in-thursdays-intraday-session
12 Health Care Stocks Moving In Thursday's...
04/18/2024 16:31:41

crude-oil-edges-lower-bio-path-holdings-shares-spike-higher
Crude Oil Edges Lower; Bio-Path Holdings S...
04/18/2024 16:08:16

once-valued-at-billions-23andmes-ceo-considers-privatization-to-secure-companys-future
Once Valued At Billions, 23andMe's CEO Con...
04/18/2024 16:06:23

Anne Wojcicki, CEO of 23andMe mulls taking the genetics company private amid market challenges. With declining revenue and a fo...

why-las-vegas-sands-shares-are-trading-lower-by-around-7-here-are-other-stocks-moving-in-thursdays-mid-day-session
Why Las Vegas Sands Shares Are Trading Low...
04/18/2024 15:32:50

12-health-care-stocks-moving-in-thursdays-pre-market-session
12 Health Care Stocks Moving In Thursday's...
04/18/2024 12:09:32

23andme-reveals-ceos-intention-to-pursue-potential-take-private
23andMe Reveals CEO's Intention To Pursue ...
04/18/2024 12:05:19

Wojcicki currently owns shares constituting more than 20% of the total outstanding shares and entitling her to approximately 49...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

08/05/2024 Marinus Pharmaceuticals, Inc. (MRNS)

NEW CASE INVESTIGATION

Ooma Inc (OOMA) AnaptysBio Inc (ANAB)